NVE Corporation（NVEC）Q2 FY2027 收入同比下滑 8%、防务销售暴跌 95%，盘后已重挫约 24%

Earnings Call Insights: NVE Corporation (NVEC) Q2 fiscal 2027 Management view “We’re pleased to report solid revenue and earnings for the quarter, driven by a 67% increase in distributor sales.” (CEO, President & Director Peter Eames) “Net margins increased to 54% due to a decrease in our effective tax rate.” (CEO, President & Director Peter Eames) “Total revenue for the quarter decreased 8% compared to the prior year quarter.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “The decrease in product sales was due to a short-term inventory adjustment at one of our large medical device customers and a 95% decrease in defense product sales.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Looking forward, we expect medical device and defense sales to recover in the current quarter, and we expect revenues in the second half of the fiscal year to be consistent with the first half.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “This quarter, we announced 2 new products.” (CEO, President & Director Peter Eames) “The new sensor provides analog information, such as position, from the motion or changes of external magnetic fields.” (CEO, President & Director Peter Eames) “These sensors are the smallest products we’ve ever made at NVE, measuring just 0.55 millimeters square.” (CEO, President & Director Peter Eames) “We also released a family of gear sensors in the past quarter for precise motion speed and position sensing in industrial automation and robotics.” (CEO, President & Director Peter Eames) “I was elected Director and appointed President and CEO at our annual shareholders’ meeting in August.” (CEO, President & Director Peter Eames) “Former CEO Dan Baker replaced Terry Glarner as Chairman.” (CEO, President & Director Peter Eames) “We also elected a new Director, Carolyn Valentine, expanding the board from 5 to 7 Directors.” (CEO, President & Director Peter Eames) Outlook “We expect medical device and defense sales to recover in the current quarter.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “We expect revenues in the second half of the fiscal year to be consistent with the first half.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “We do see the order disruptions as a temporary situation, and we expect to return to growth in the next quarter.” (CEO, President & Director Eames) “We expect our effective tax rate to be between 14% and 16% for at least the remainder of the fiscal year.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) Compared with the prior quarter’s tone of acceleration, the company’s framing shifted toward normalizing timing effects: “The order variability was primarily from orders being pulled into quarter 1 from quarter 2.” (CEO, President & Director Eames) and “We do not see any further disruptions looking forward.” (CEO, President & Director Eames) Financial results “Net income for the second quarter of fiscal 2027 was $3.17 million, or $0.65 per diluted share, compared to $3.31 million, or $0.68 per share in the prior year quarter.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Total revenue for the quarter decreased 8% compared to the prior year quarter.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “The decrease was due to a 9% decrease in product sales, partially offset by a 25% increase in contract R&D revenue.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Total operating expenses increased 4%... due to a 44% increase in selling, general, and administrative expense, partially offset by a 17% decrease in R&D expense.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “The decrease in R&D was due to staffing redeployment.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Our effective tax rate... decreased to 14% from 20% in the prior year quarter, primarily due to favorable tax law changes.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Gross margin was 78%, operating margin was 55%, and pre-tax margin was 63%.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “For the first 6 months of fiscal 2027, total revenue was $16.9 million, up 36% over the same period in fiscal 2026.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Net income was $9.57 million, or $1.97 per diluted share for the first 2 quarters of fiscal 2027.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Cash flow from operations was $11.1 million for the first 6 months of fiscal 2027, compared to $8 million for the first 6 months of fiscal 2026.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “Cash plus marketable securities increased from $43.5 million to $44.4 million...” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) “We paid our $1 per share quarterly dividend the past quarter and declare another dividend to be paid at the end of November.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) Q&A Unknown Analyst: “Were those pushed out into H2 and not necessarily into next fiscal year?” Title Eames: “The order variability was primarily from orders being pulled into quarter 1 from quarter 2.” Unknown Analyst: “Would you say that September was the strongest month of the quarter?” Title Nelson: “We did see revenue increase towards the end of the September quarter... we did see an increase in September compared to... August.” Unknown Analyst: “Would you guys give some color around the growth you’re seeing in the automation market... and the power conversion markets...?” Title Eames: “We’re definitely seeing strong growth in both power conversion and in robotics applications.” Unknown Analyst: “Would you give some color on maybe any design wins...?” Title Eames: “We do have some important, small design wins for those products.” Unknown Analyst: “Would you size very high volumes?” Title Eames: “We’re certainly not unfamiliar with producing millions of sensors, and tens of millions of sensors are certainly well within our capacity here.” Ittai Eden, Principal: “...the second half... top line should be similar to the first half...?” Title Eames: “That’s correct.” Ittai Eden, Principal: “Is there any color you can give on backlog...?” Title Eames: “We typically don’t track a backlog.” Ittai Eden, Principal: “...capacity expansion... has that moved into volume production...?” Title Eames: “There certainly has been some shift towards production capacity... the shift is relatively small now.” Unknown Attendee: “...vision now for the company... differ?” Title Eames: “It is a continuation of our previous efforts and my efforts on the expansion in general.” Unknown Analyst: “...dollar content per robot...?” Title Eames: “A typical NVE product ASP is perhaps $1 to $2 per sensor.” and “Certainly in the tens of sensors, I think is fair.” Sentiment analysis Analysts: slightly positive, with repeated probing on timing, visibility, and customer concentration, including “Is there any color you can give on backlog or backlog coverage...?” (Ittai Eden, Principal) and “Would you be able to put any directional numbers to that...?” (Unknown Analyst) Management: slightly positive in prepared remarks and generally confident in Q&A, pairing optimism with limits on disclosure: “We’re definitely seeing strong growth...” (CEO, President & Director Eames) and “We typically don’t track a backlog.” (CEO, President & Director Eames) Versus the prior quarter, management language appeared less celebratory and more focused on explaining variability, shifting from “We’re pleased to report exceptional results.” (CEO, President & Director Daniel Baker) to “Inventory adjustments... can create short-term order volatility for us.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) Quarter-over-quarter comparison Leadership changes moved from planned to completed: “Last month, we announced that I’m retiring as President and CEO...” (CEO, President & Director Daniel Baker, prior quarter) versus “I was elected Director and appointed President and CEO...” (CEO, President & Director Eames, current quarter). The growth narrative shifted from sharp expansion to mixed comparisons: “first quarter total revenue increased 81% to $11 million...” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson, prior quarter) versus “Total revenue for the quarter decreased 8%...” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson, current quarter). Analyst focus tightened around timing and visibility in the current call (rescheduled orders, backlog, mix), while the prior call’s questions leaned toward sustainability of a higher run-rate: “...likelihood that this represents a new higher... plateau...” (Walter Morris, prior quarter). Risks and concerns Customer and end-market volatility remained central: “Inventory adjustments by medical device customers can create short-term order volatility for us.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) and “Defense product sales can be highly variable because of government procurement cycles.” (Accounting Manager & Principal Financial Officer and Controller Daniel Nelson) Concentration risk was reiterated through cautionary framing: “our reliance on several large customers for a significant percentage of revenue” (CEO, President & Director Eames) and investor questioning on Abbott exposure, followed by “we see growth in other areas as well... such as neurostimulators.” (CEO, President & Director Eames) Final takeaway Management framed the quarter as a combination of short-term customer ordering effects and strengthening broader demand, emphasizing a 67% increase in distributor sales, new sensor launches aimed at robotics and automation, and expectations for medical and defense sales recovery. The company guided that second-half revenue should be consistent with the first half and set an effective tax rate expectation of 14% to 16% for at least the remainder of the fiscal year, while repeatedly signaling that design wins and robotics-related volumes are still in ramp stages rather than fully visible through backlog metrics. Read the full Earnings Call Transcript